Quarterhill Files Final Base Shelf Prospectus
As previously announced, the final base shelf prospectus allows the Company to qualify the distribution by way of prospectus in Canada of up to C$200 million of common shares, preferred shares, debt securities, warrants, subscription receipts, units, or any combination thereof, during the 25-month period that the base shelf prospectus is effective. The specific terms of any offering under the base shelf prospectus will be established in a prospectus supplement, which will be filed with the applicable Canadian securities regulatory authorities in connection with any such offering.
The shelf prospectus will enable the Company to access new capital or issue securities in connection with strategic acquisitions, if and when needed. The amount and timing of any future offerings or issuances will be based on the Company's financial requirements and market conditions at that time.
A copy of the final short form base shelf prospectus can be found on SEDAR+ at www.sedarplus.ca.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Quarterhill
Quarterhill is a leading provider of tolling, safety and enforcement, and logistics solutions in the Intelligent Transportation System (ITS) industry. Our goal is technology-driven global leadership in ITS, via organic growth of our businesses, and by continuing an acquisition-oriented investment strategy that capitalizes on attractive growth opportunities within ITS and its adjacent markets. Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF. For more information: www.quarterhill.com.
Forward-looking Information
This news release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). Such forward-looking statements relate to future events, conditions or future financial performance of Quarterhill based on future economic conditions and courses of action. All statements other than statements of historical fact may be forward-looking statements. Such forward-looking statements are often, but not always, identified by the use of any words such as "seek", "anticipate", "budget", "plan", "goal", "expect" and similar expressions. Specifically, this news release contains forward-looking statements relating to, but not limited to: the filing and effectiveness of any potential prospectus supplement in the future; future financing opportunities; the amount and terms of any securities to be offered under one or more shelf prospectus supplement(s); and the Company's focus on its acquisition strategy.
Forward-looking statements involve known and unknown risks, assumptions, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Material risk factors that could cause actual results to differ materially from the forward-looking statements contained in this news release include, among others, demand for Quarterhill's products and services; general economic and market conditions; competition; risks relating to technological advances and cyber-security; force majeure risks; and other risks set forth in the Company's most recent annual information form available on SEDAR+ at www.sedarplus.ca. The Company believes the expectations reflected in the forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. Material factors and assumptions used to develop the forward-looking statements contained in this news release include, among others: Quarterhill's ability to execute on its business plan; demand for Quarterhill's products and services; operating assumptions; and financial projections and cost estimates. These foregoing lists are not exhaustive. Additional information on these and other factors which could affect the Company's operations or financial results are included in the Company's most recent annual information form and other public documents on file with the Canadian Securities regulatory authorities on www.sedarplus.ca.
The forward-looking statements represent the Company's views as at the date of this news release. There can be no assurance that forward-looking statements will prove to be accurate, as actual events and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on any forward-looking statement. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
8 minutes ago
- Cision Canada
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
SAN DIEGO and CALGARY, AB, July 22, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY." As previously announced, the Company was notified by Nasdaq on February 13, 2025, that the Company's common shares failed to maintain a minimum bid price of US$1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. According to the Compliance Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company's common shares has been at or above $1.00 per share for 10 consecutive business days, from July 8, 2025, through July 21, 2025, and the matter is now closed. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected]


Cision Canada
20 minutes ago
- Cision Canada
IGM Financial announces change in the time of second quarter 2025 results conference call on August 7 Français
WINNIPEG, MB, July 22, 2025 /CNW/ - IGM Financial Inc. (TSX: IGM) today announced a change in the timing of its 2025 second quarter results conference call. The live webcast will now take place at 9 a.m. ET on Thursday, August 7, 2025, one hour later than originally scheduled. As previously announced, IGM will release its second quarter 2025 earnings after markets close on Wednesday, August 6, 2025. Please pre-register for the webcast (Register) to obtain a calendar booking with your dial-in numbers and unique PIN. Your call will be connected on a listen-only basis. Should you miss the conference call, a playback will be available by calling 1-855-669-9658 from August 7, 2025 at 5 p.m. CT/6 p.m. ET until September 7, 2025. Please use passcode 7389730. An archived version of the webcast will also be available on IGM Financial Inc.'s website. ABOUT IGM FINANCIAL INC. IGM Financial Inc. ("IGM", TSX: IGM) is a leading Canadian diversified wealth and asset management organization with approximately $284 billion in total assets under management and advisement as of June 30, 2025. The company is committed to bettering the lives of Canadians by better planning and managing their money. To achieve this, IGM provides a broad range of financial planning and investment management services to help approximately two million Canadians meet their financial goals. IGM's activities are carried out principally through IG Wealth Management and Mackenzie Investments and are complimented by strategic positions in wealth managers Rockefeller Capital Management and Wealthsimple and asset managers ChinaAMC and Northleaf Capital. These strengthen IGM's capabilities, reach and diversification. IGM is a member of the Power Corporation group of companies. For more information, visit


Toronto Star
an hour ago
- Toronto Star
LexisNexis Launches Protégé in Canada: A Secure, Personalized AI Assistant That Automates Legal Work and Amplifies Lawyer Productivity
Toronto, ON, July 22, 2025 (GLOBE NEWSWIRE) — LexisNexis® Legal & Professional, a leading global provider of AI-powered legal analytics and decision tools, today announces a range of enhancements to Lexis+ AI™ and the Canadian launch of LexisNexis Protégé™. This follows the successful launches of Protégé in the USA, Australia, and the UK. The personalized AI assistant intelligently supports legal practitioners in drafting, researching and advising their clients faster and more accurately, helping them focus on higher-value work. Built with the highest levels of security, compliance and privacy, Protégé is now available in the Lexis+ AI legal workflow solution and will soon be available in the Microsoft Word drafting solution, Lexis® Create+.